Quantcast

Industry news that matters to you.  Learn more

Edimer Pharmaceuticals Presents Study Results on Non-Invasive Sweat Gland Analysis as a Biomarker in XLHED Patients

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia. The study reported on the use of non-invasive technologies for quantitative sweat function, and correlated these results with the nature and location of ectodysplasin A (EDA) gene defects associated with XLHED. Data analysis confirmed a consistent, quantifiable defect in sweat gland function as a disease biomarker in XLHED patients, even in the setting of normal sweat pore counts. The study outcomes were reported at the 60th Annual Meeting of the American Society of Human Genetics (ASHG) in Washington, D.C.

Neogenix Oncology to Present Data on the Detection of Colorectal and Pancreatic Cancer at ASCO’s 2010 Annual Meeting on Molecular Makers in Cancer

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

DiagnoCure’s PCA3 Prostate Cancer Biomarker Submitted By Gen-Probe to the U.S. Food and Drug Administration

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that its commercial partner, Gen-Probe Incorporated, has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer. DiagnoCure holds the worldwide rights to the PCA3 biomarker and, in 2003, granted an exclusive sub-license to Gen-Probe for diagnostic applications.

Chronix Biomedical Adds State-of-the-art Mass Seqeuncing Capabilities to Accelerate Development of it’s DNA Biomakers for Early Detection of Cancer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany’s first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix’s long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac’s Diagnostics division for the Company’s doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool. Selection for treatment with AEZS-108 is determined on the basis of LHRH receptor expression, currently measured immunohistochemically. In humans, LHRH receptors are expressed in ovarian, endometrial, breast, bladder, prostate and pancreatic tumors. AEZS-108 is currently in Phase 2 trials for advanced LHRH receptor positive ovarian and endometrial cancer.